INT6748

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 1990
Last Reported 2010
Negated 3
Speculated 2
Reported most in Abstract
Documents 15
Total Number 17
Disease Relevance 2.63
Pain Relevance 11.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Dio1) endoplasmic reticulum (Dio1)
Anatomy Link Frequency
NAc 2
neurons 1
neocortex 1
Spinal cord 1
Dio1 (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 143 100.00 Very High Very High Very High
Nucleus accumbens 8 100.00 Very High Very High Very High
antagonist 34 99.96 Very High Very High Very High
Enkephalin 83 99.92 Very High Very High Very High
Morphine 20 99.82 Very High Very High Very High
nMDA receptor 3 99.80 Very High Very High Very High
dopamine receptor 45 99.74 Very High Very High Very High
tolerance 8 99.44 Very High Very High Very High
Analgesic 28 99.24 Very High Very High Very High
Spinal cord 5 98.96 Very High Very High Very High
Disease Link Frequency Relevance Heat
Targeted Disruption 90 99.48 Very High Very High Very High
Age-related Macular Degeneration 44 97.40 Very High Very High Very High
Disease 30 90.32 High High
Sleep Disorders 26 85.60 High High
Rupture 1 66.08 Quite High
Body Weight 11 51.12 Quite High
INFLAMMATION 16 25.00 Low Low
Sprains And Strains 4 13.00 Low Low
Anxiety Disorder 38 5.00 Very Low Very Low Very Low
Catalepsy 28 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Striatal dopaminergic activity was evaluated by measuring: a) the ratio between the amounts of L-3,4-dihydroxyphenylacetic acid (DOPAC), the main intraneuronal metabolite of dopamine (DA), and the neurotransmitter itself, as an index of presynaptic activity; and b) the number and affinity of D1 and D2 dopaminergic receptors, as well as the amount of their coupled second messenger, cyclic adenosine monophosphate (cAMP), as postsynaptic parameters.
Regulation (affinity) of D1 associated with adenocard, neurotransmitter and dopamine
1) Confidence 0.45 Published 1992 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 1332081 Disease Relevance 0 Pain Relevance 0.91
The down-regulation of dopamine receptors was selective for D2 dopamine receptors, since treatment with SKF38393 had no significant effects on either D1 or D2 dopamine receptors, nor did it alter the messenger RNAs for the D1 and D2 receptors.
Neg (nor) Regulation (alter) of D1 associated with dopamine receptor
2) Confidence 0.40 Published 1993 Journal Neuroscience Section Abstract Doc Link 8101360 Disease Relevance 0 Pain Relevance 0.77
Spinal cord excitation was induced in mice by morphine and the effects of dopamine D1 and D2 receptor antagonists on the Straub tail reaction were investigated.
Regulation (effects) of D1 in Spinal cord associated with dopamine, antagonist, morphine and spinal cord
3) Confidence 0.29 Published 1990 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2150374 Disease Relevance 0 Pain Relevance 0.65
Neurochemical changes in dopamine D1, D3 and D1/D3 receptor knockout mice.
Regulation (changes) of D1 associated with targeted disruption, dopamine and enkephalin
4) Confidence 0.27 Published 2003 Journal Eur. J. Pharmacol. Section Title Doc Link 12860471 Disease Relevance 0.38 Pain Relevance 1.45
Neurochemical changes in dopamine D1, D3 and D1/D3 receptor knockout mice.
Regulation (changes) of D1 associated with targeted disruption, dopamine and enkephalin
5) Confidence 0.27 Published 2003 Journal Eur. J. Pharmacol. Section Title Doc Link 12860471 Disease Relevance 0.38 Pain Relevance 1.45
However, it failed to alter the levels of either D1 or D2 dopamine receptor mRNA.
Neg (failed) Regulation (alter) of D1 associated with dopamine receptor
6) Confidence 0.21 Published 1995 Journal Biol. Psychiatry Section Abstract Doc Link 7619972 Disease Relevance 0 Pain Relevance 0.50
The down-regulation of dopamine receptors was selective for D2 dopamine receptors, since treatment with SKF38393 had no significant effects on either D1 or D2 dopamine receptors, nor did it alter the messenger RNAs for the D1 and D2 receptors.
Neg (no) Regulation (effects) of D1 associated with dopamine receptor
7) Confidence 0.21 Published 1993 Journal Neuroscience Section Abstract Doc Link 8101360 Disease Relevance 0 Pain Relevance 0.71
The effects of the dopamine D1 antagonist SCH23390 and the D2 antagonist sulpiride on the rewarding effects of delta opioid receptor agonists were examined in mice.
Spec (examined) Regulation (effects) of D1 associated with dopamine, antagonist, agonist and opioid receptor
8) Confidence 0.20 Published 1996 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 8740041 Disease Relevance 0 Pain Relevance 0.76
The effects of dopamine D1 and D2 receptor antagonists on the rewarding effects of delta 1 and delta 2 opioid receptor agonists in mice.
Regulation (effects) of D1 associated with dopamine, antagonist, agonist, enkephalin and opioid receptor
9) Confidence 0.20 Published 1996 Journal Psychopharmacology (Berl.) Section Title Doc Link 8740041 Disease Relevance 0 Pain Relevance 0.96
, which is in agreement with the expected recombination pattern induced by Cre recombinase under the control of D1 regulatory sequences [36].
Regulation (control) of D1
10) Confidence 0.16 Published 2007 Journal PLoS Biology Section Body Doc Link PMC2001214 Disease Relevance 0.07 Pain Relevance 0.10
In particular, Cre-mediated recombination under the control of D1 regulatory sequences occurs also in layer VI of the neocortex [36,37].
Regulation (control) of D1 in neocortex
11) Confidence 0.16 Published 2007 Journal PLoS Biology Section Body Doc Link PMC2001214 Disease Relevance 0 Pain Relevance 0.13
Our results suggest that the inhibitory effects of berberine on morphine-induced locomotor sensitization and analgesic tolerance are closely related to the modulation of D1 and NMDA receptors, and that berberine should be viewed as a potential novel means of attenuating morphine-induced sensitization and analgesic tolerance.
Regulation (modulation) of D1 associated with nmda receptor, analgesic, tolerance and morphine
12) Confidence 0.16 Published 2006 Journal Neuroscience Section Abstract Doc Link 16934942 Disease Relevance 0 Pain Relevance 1.54
We found that there was no difference in NAc D1 levels between any of the mGluR5 genotypes (Supporting Information S1), suggesting that changes in NAc D1 content did not contribute to the phenotypes observed in OSS.
Regulation (changes) of D1 in NAc associated with nucleus accumbens
13) Confidence 0.15 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2994905 Disease Relevance 0.54 Pain Relevance 0.39
To examine the effects of neuroprotectin D1 (NPD1), a stereospecific derivative of docosahexaenoic acid, on choroidal neovascularization (CNV) in a laser-induced mouse model.
Regulation (effects) of neuroprotectin D1 associated with age-related macular degeneration
14) Confidence 0.12 Published 2010 Journal Molecular Vision Section Abstract Doc Link PMC2834569 Disease Relevance 0.46 Pain Relevance 0
To determine if D1 levels were altered in mGluR5 Het and KO mice, tissue from the nucleus accumbens (NAc) of naïve mice was taken and probed for levels of D1 protein.
Regulation (altered) of D1 in NAc associated with targeted disruption and nucleus accumbens
15) Confidence 0.09 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2994905 Disease Relevance 0.52 Pain Relevance 0.33
The present work demonstrates with the help of bacterial artificial chromosome (BAC) transgenic mice expressing enhanced green fluorescent protein (eGFP) under the control of D1 or D2 receptor promoters (BAC D1 or D2 eGFP mice), large, distinct and clear differences between the corticostriatal responses from direct and indirect pathway neurons.
Spec (clear) Regulation (control) of D1 in neurons associated with targeted disruption
16) Confidence 0.05 Published 2010 Journal Frontiers in Systems Neuroscience Section Body Doc Link PMC2893005 Disease Relevance 0.10 Pain Relevance 0.38
Our main hypothesis is that dopamine promotes sleep by its action on the D2 receptors in the BG and promotes wakefulness by its action on D1 and D2 receptors in the extra-BG sites.
Regulation (action) of D1 associated with dopamine
17) Confidence 0.01 Published 2010 Journal Frontiers in Neuroanatomy Section Abstract Doc Link PMC2996256 Disease Relevance 0.18 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox